BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees inducement options to purchase an aggregate of 240,500 shares of BioCryst common stock on December 31, 2020 as inducements material to each employee entering into employment with BioCryst.

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the closing of its in vivo gene editing research collaboration and exclusive license agreement with Eli Lilly and Company following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended

TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors.

Kala Pharmaceuticals Announces Availability of EYSUVIS TM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline -- First and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in pharmacies nationwide -- -- Advancing multiple NCE development programs targeted to address front and back of eye diseases --

-- Proceeds support advancement of Precision Oncology 2.0 drug-hunting engine and first wave of therapeutic candidates -- -- Company management to present at 39 th Annual J.P. Morgan Healthcare Conference --

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.

– Commercial Readiness Nearing Completion in Support of Potential Tivozanib U.S. Launch – – Updated IP Strategy Offers Potential for Tivozanib Patent Term Extension to November 2028 – – Corinne D. Epperly, MD, MPH, Appointed to Board of Directors – – Phase 2 Open Label Randomized Study of Ficlatuzumab in HNSCC Enrollment Complete; Plans to Announce Results and Phase 3 Decision on Track for Mid-2021 –

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that Selwyn M. Vickers, M.D., F.A.C.S., has been elected to serve on the company’s board of directors.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the H.C. Wainwright BioConnect 2021 Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel discussion on precision medicine on Wednesday, January 13, 2021 at 9:00 a.m. PT / 12:00 p.m. ET. T